Abstract
Now we come to the most important aspect of all. Can the new findings lead to formulation of innovative treatments to alter the course of, or possibly even eradicate, the disease?
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kuo C-C, Grayston JT. In vitro drug susceptibility of Chlamydia strain TWAR. Antimicrobial Agents Chemother 1988;32(2):257–258.
Strigl S, Roblin PM, Reznik T. In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae. Antimicrob Agents Chemother 2000;44(4):1112–1113.
Stewart CE, Coleman K, Mortenson J. Effect of extended pre-incubation with Chlamydia pneumoniae and extended incubation with antimicrobials on the minimum inhibitory concentration (MIC) of five antimicrobials. Diagn Microbiol Infect Dis 2001;40:207–209.
Cuffini C, Alberto Guzman L, Villegas N, et al. Isolation of Chlamydia pneumoniae from atheromas of the carotid artery and their antibiotics susceptibility profile. Enferm Infecc Microbiol Clin 2006;24(2):81–85.
Gieffers J, Solbach W, Maass M. In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic arteries. Antimicrob Agents Chemother 1998;42(10):2762–2764.
Kutlin A, Roblin PM, Hammerschlag MR. Effect of prolonged treatment with azithromycin, clarithromycin or levofloxacine on Chlamydia pneumoniae in a continuous-infection model. Antimicrob Chemother 2002;46(2):409–412.
Kutlin A, Kohlhoff S, Roblin P, et al. Emergence of resistance to rifampicin and rifalazil in Chlamydia pneumoniae and Chlamydia trachomatis. Antimicrob Agents Chemother 2005;49(3):903–907.
Yamaguchi H, Friedman H, Yamamoto M, et al. Chlamydia pneumoniae resists antibiotics in lymphocytes. Antimicrob Agents Chemother 2003;47(6):1972–1975.
Gieffers J, Fullgraf H, Jahn J, et al. Chlamydia pneumoniae infection in circulating monocytes is refractory to antibiotic treatment. Circulation 2001;103(3):351–356.
Hogan RJ, Mathews SA, Mukhopadhyay S, et al. Chlamydial persistence: beyond the biphasic paradigm. Infect Immun 2004;72(4):1843–1855.
Krull M, Maass M, Suttorp N, et al. Chlamydophila pneumoniae. mechanism of target cell infection and activation. Thromb Haemost 2005;2:319–326.
Wendelhag I, Wiklund O, Winklund J. On quantifying plaque size and intima-media thickness in carotid and femoral arteries. Arterioscler Thromb Vasc Biol 1996;16(7):843–850.
Rights and permissions
Copyright information
© 2007 Springer-Verlag London Limited
About this chapter
Cite this chapter
(2007). Treatment. In: Chlamydia Atherosclerosis Lesion. Springer, London. https://doi.org/10.1007/978-1-84628-810-4_21
Download citation
DOI: https://doi.org/10.1007/978-1-84628-810-4_21
Publisher Name: Springer, London
Print ISBN: 978-1-84628-809-8
Online ISBN: 978-1-84628-810-4
eBook Packages: MedicineMedicine (R0)